Kidney Research UK

Their core work

Kidney Research UK is a Peterborough-based charity and research organisation focused exclusively on kidney disease — from bench to bedside. They fund and facilitate research into chronic kidney disease, peritoneal dialysis, and renal regenerative therapies, and they bring something rare to EU consortia: direct access to UK patient populations, disease registries, and clinical networks. In H2020, they participated as third-party contributors to MSCA training networks, meaning they hosted early-stage researchers and provided disease expertise, human tissue access, and clinical context that academic labs cannot replicate on their own.

What they specialise in

How they've shifted over time

In their earlier H2020 engagement (2018), Kidney Research UK contributed to preclinical and technology development work — specifically cell tracking, mesenchymal stem cell therapies, and imaging tools for evaluating regenerative treatments before they reach patients. By 2019 their involvement shifted toward clinical and translational research: patient registries, real-world outcomes in dialysis populations, personalised medicine, and Phase I/II study frameworks. This reflects a maturation from supporting laboratory-stage research toward anchoring clinical relevance in research consortia — a natural trajectory for a disease charity with deep ties to patient networks and clinicians.

Kidney Research UK is moving toward real-world evidence and personalised medicine frameworks, making them increasingly valuable to any consortium that needs clinical translation, patient data governance, or disease registry infrastructure in the kidney space.

How they like to work

Kidney Research UK participates exclusively as a third party in H2020 projects — never as a formal coordinator or named participant — which reflects the typical role of a disease charity: providing specialist clinical environment, patient access, and disease advocacy rather than leading research delivery. Despite this limited formal role, they have accumulated 33 unique consortium partners across 12 countries, suggesting they are actively sought out as a valued contributor. Organisations considering them as a partner should expect a specialist-contributor model: deep domain knowledge and patient-facing assets, but not project management leadership.

Kidney Research UK has connected with 33 unique organisations across 12 countries through just two MSCA training networks — an unusually broad reach for a third-party contributor, indicating their disease expertise draws diverse European research teams. Their network is predominantly academic and clinical, centred on the European renal research community.

What sets them apart

Kidney Research UK occupies a rare niche: a disease-specific charity that bridges the gap between laboratory researchers and kidney patients at scale, offering what most academic partners cannot — organised patient cohorts, disease registries, and a trusted relationship with the UK nephrology community. For any consortium working on kidney disease, renal regeneration, or dialysis innovation, they provide instant legitimacy and patient-facing infrastructure. Their non-commercial, charity status also makes them a natural partner for projects that need public engagement or patient advocacy components.

Highlights from their portfolio

• IMPROVE-PD
  Addresses the high-mortality intersection of peritoneal dialysis, cardiovascular risk, and personalised medicine — a clinically urgent area where patient registry access (which Kidney Research UK can provide) is the critical bottleneck.
• RenalToolBox
  An MSCA training network developing the next generation of cell therapy assessment tools for kidney disease, spanning mesenchymal stem cells, nanoparticle cell tracking, and multimodal imaging — demonstrating Kidney Research UK's ability to contribute to deep-technology consortia.